Danish pharma bemoans lack of PM comment on unitary European patent system
It could be crucially important for growth, exports and employment in Denmark. But not a word was said about the unitary European patent system when Prime Minister Helle Thorning-Schmidt (pictured) set out the course for 2014 in her New Year's speech, observes the Danish Association of the Pharmaceutical Industry (LIF) in a web posting.
Should Denmark sign up to the unitary European patent system or not? That is the question that Danes are to consider at a referendum on May 25, 2014. And the result of this referendum could have a major impact on Danish companies' competitiveness and for growth, exports and employment.
Even so, not a single word about the issue was mentioned in Prime Minister Helle Thorning-Schmidt's New Year's speech, which Thomas Klit Christensen, chief legal consultant at the LIF, feels is a shame.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze